In vitro synergy testing of novel antimicrobial combination therapies against neisseria gonorrhoeae

Journal of Antimicrobial Chemotherapy

Volumn 69, Issue 6, 2014, Pages 1572-1578

  Barbee, Lindley A ^a,b   Soge, Olusegun O ^a   Holmes, King K ^a   Golden, Matthew R ^a,b  

^a UNIVERSITY OF WASHINGTON   (United States)

^b PUBLIC HEALTH SEATTLE AND KING COUNTY   (United States)

Author keywords

Antimicrobial resistance; Novel therapies; Sexually transmitted diseases

Indexed keywords

AZITHROMYCIN; CEFIXIME; CEFTRIAXONE; DOXYCYCLINE; FOSFOMYCIN; GENTAMICIN; RIFAMPICIN; ANTIINFECTIVE AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG POTENTIATION; EPSILOMETER TEST; IN VITRO STUDY; NEISSERIA GONORRHOEAE; NONHUMAN; DRUG COMBINATION; DRUG EFFECTS; DRUG INTERACTION; FEMALE; GONORRHEA; HUMAN; ISOLATION AND PURIFICATION; MALE; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; ANTI-INFECTIVE AGENTS; DRUG INTERACTIONS; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; GONORRHEA; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; NEISSERIA GONORRHOEAE;

EID: 84900500899     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkt540     Document Type: Article

References (47)

1. CDC. Sexually Transmitted Disease Surveillance, 2011. http://www.cdc. gov/std/stats11/Surv2011.pdf (16 December 2013, date last accessed).
2. CDC. Antibiotic Resistance Threats in the United States, 2013. http://www. cdc.gov/drugresistance/threat-report-2013/pdf/ar-threats-2013-508.pdf (27 November 2013, date last accessed).
3. Workowski KA, Berman SM, Douglas JM Jr. Emerging antimicrobial resistance in Neisseria gonorrhoeae: urgent need to strengthen prevention strategies. Ann Intern Med 2008; 148: 606-13.
4. CDC. Update to CDC's Sexually Transmitted Diseases Treatment Guidelines, 2010: oral cephalosporins no longer a recommended treatment for gonococcal infections. MMWR Morb Mortal Wkly Rep 2012; 61: 590-4.
5. Furuya R, Nakayama H, Kanayama A et al. In vitro synergistic effects of double combinations of β-lactams and azithromycin against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2006; 12: 172-6.
6. Golparian D, Hadad R, Hellmark B et al. In vitro antimicrobial synergy testing, using Etest methodology, of Neisseria gonorrhoeae for evaluation of susceptibility when using dual antimicrobial therapy. In: Sexually Transmitted Infections, Vol. 89 Suppl 1. STI & AIDS World Congress, Vienna, Austria, 2013. Abstract P2.087, p. A114. International Society for Sexually Transmitted Diseases Research.
7. Furuya R, Koga Y, Irie S et al. In vitro activities of antimicrobial combinations against clinical isolates of Neisseria gonorrhoeae. J Infect Chemother 2013; 19: 1218-20.
8. Pereira R, Cole MJ, Ison CA. Combination therapy for gonorrhoea: in vitro synergy testing. J Antimicrob Chemother 2013; 68: 640-3.
9. Wind C, de Vries H, van Dam A. In vitro synergy determination for dual antibiotic therapy against resistant Neisseria gonorhoeae using Etest and agar dilution. In: Sexually Transmitted Infections, Vol. 89 Suppl 1. STI & AIDS World Congress, Vienna, Austria, 2013. Abstract O21.4, p. A67. International Society for Sexually Transmitted Disease Research.
10. Barbee LA, Kerani RP, Dombrowski JC et al. A retrospective comparative study of 2-drug oral and intramuscular cephalosporin treatment regimens for pharyngeal gonorrhea. Clin Infect Dis 2013; 56: 1539-45.
11. Sathia L, Ellis B, Phillip S et al. Pharyngeal gonorrhoea-is dual therapy the way forward? Int J STD AIDS 2007; 18: 647-8.
12. Schumacher CM, Ghanem KG. Retreatment rates for uncomplicated gonorrhea infection: comparing ceftriaxone and azithromycin versus ceftriaxone and doxycycline. Sex Transm Dis 2013; 40: 539-45.
13. Bolan GA, Sparling PF, Wasserheit JN. The emerging threat of untreatable gonococcal infection. N Engl J Med 2012; 366: 485-7.
14. Soge OO, Harger D, Schafer S et al. Emergence of increased azithromycin resistance during unsuccessful treatment of Neisseria gonorrhoeae infection with azithromycin (Portland, OR, 2011). Sex Transm Dis 2012; 39: 877-9.
15. Yuan LF, Yin YP, Dai XQ et al. Resistance to azithromycin of Neisseria gonorrhoeae isolates from 2 cities in China. Sex Transm Dis 2011; 38: 764-8.
16. Starnino S, Galarza P, Carvallo ME et al. Retrospective analysis of antimicrobial susceptibility trends (2000-2009) in Neisseria gonorrhoeae isolates from countries in Latin America and the Caribbean shows evolving resistance to ciprofloxacin, azithromycin and decreased susceptibility to ceftriaxone. Sex Transm Dis 2012; 39: 813-21.
17. Unemo M, Golparian D, Hellmark B. First three Neisseria gonorrhoeae isolates with high-level resistance to azithromycin in Sweden: a threat to currently available dual-antimicrobial regimens for treatment of gonorrhea? Antimicrob Agents Chemother 2014; 58: 624-5.
18. Brandt CM, Rouse MS, Tallan BM et al. Effective treatment of cephalosporin-rifampin combinations against cryptic methicillinresistant β-lactamase-producing coagulase-negative staphylococcal experimental endocarditis. Antimicrob Agents Chemother 1995; 39: 1815-9.
19. Rand KH, Houck H. Daptomycin synergy with rifampicin and ampicillin against vancomycin-resistant enterococci. J Antimicrob Chemother 2004; 53: 530-2.
20. Anadiotis L, Maskell JP, Sefton AM. Comparative in-vitro activity of penicillin alone and combined with gentamicin against clinical isolates of Streptococcus pneumoniae with decreased susceptibility to penicillin. Int J Antimicrob Agents 2002; 19: 173-81.
21. Angehrn P. In vitro and in vivo synergy between ceftriaxone and aminoglycosides against Pseudomonas aeruginosa. Eur J Clin Microbiol 1983; 2: 489-95.
22. Kastoris AC, Rafailidis PI, Vouloumanou EK et al. Synergy of fosfomycin with other antibiotics for Gram-positive and Gram-negative bacteria. Eur J Clin Pharmacol 2010; 66: 359-68.
23. Kikuchi K, Totsuka K, Shimizu K et al. Effects of combination of benzylpenicillin and fosfomycin on penicillin-resistant Streptococcus pneumoniae. Microb Drug Resist 1995; 1: 185-9.
24. Unemo M, Fasth O, Fredlund H et al. Phenotypic and genetic characterization of the 2008 WHO Neisseria gonorrhoeae reference strain panel intended for global quality assurance and quality control of gonococcal antimicrobial resistance surveillance for public health purposes. J Antimicrob Chemother 2009; 63: 1142-51.
25. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically-Ninth Edition: Approved Standard M07-A9. CLSI, Wayne, PA, USA, 2012.
26. CDC. Gonococcal Isolate Surveillance Project Protocol. http://www.cdc. gov/std/gisp/GISP-Protocol07-15-2010.pdf (2 September 2013, date last accessed).
27. White RL, Burgess DS, Manduru M et al. Comparison of three different in vitro methods of detecting synergy: time-kill, checkerboard, and E test. Antimicrob Agents Chemother 1996; 40: 1914-8.
28. Pillai SK, Moellering RC, Eliopoulos GM. Antimicrobial combinations. In: Antibiotics in Laboratory Medicine. Philadelphia, PA: Lippincott Williams & Wilkins, 2005.
29. Odds FC. Synergy, antagonism, and what the chequerboard puts between them. J Antimicrob Chemother 2003; 52: 1.
30. Chisholm SA, Quaye N, Cole MJ et al. An evaluation of gentamicin susceptibility of Neisseria gonorrhoeae isolates in Europe. J Antimicrob Chemother 2011; 66: 592-5.
31. Unemo M, Nicholas RA. Emergence of multidrug-resistant, extensively drug-resistant and untreatable gonorrhea. Future Microbiol 2012; 7: 1401-22.
32. Westbrook WG 3rd. Delay and inhibition of growth of Neisseria gonorrhoeae in vitro. Relationship of delayed incubation, penicillinase production, urine culture, and self-treatment. Br J Vener Dis 1980; 56: 83-7.
33. 2 and bicarbonate on the growth of Neisseria gonorrhoeae. J Clin Microbiol 1977; 5: 427-32.
34. 2-enriched environment on gonococci. Health Lab Sci 1976; 13: 45-8.
35. Rahal JJ Jr. Antibiotic combinations: the clinical relevance of synergy and antagonism. Medicine (Baltimore) 1978; 57: 179-95.
36. Cole MJ, Unemo M, Hoffmann S et al. The European Gonococcal Antimicrobial Surveillance Programme, 2009. Euro Surveill 2011; 16: pii=19995.
37. Brown LB, Krysiak R, Kamanga G et al. Neisseria gonorrhoeae antimicrobial susceptibility in Lilongwe, Malawi, 2007. Sex Transm Dis 2010; 37: 169-72.
38. Dowell D, Kirkcaldy RD. Effectiveness of gentamicin for gonorrhoea treatment: systematic review and meta-analysis. Sex Transm Infect 2012; 88: 589-94.
39. Kirkcaldy R. Treatment of gonorrhea in an era of emerging cephalosporin resistance and results of a randomised trial of new potential treatment options. In: Sexually Transmitted Infections, Vol. 89 Suppl 1. STI & AIDS World Congress, Vienna, Austria, 2013. Abstract S08.1, p. A14. International Society for Sexually Transmitted Diseases Research.
40. Blumberg HM, Leonard MK Jr, Jasmer RM. Update on the treatment of tuberculosis and latent tuberculosis infection. JAMA 2005; 293: 2776-84.
41. Sendi P, Zimmerli W. Antimicrobial treatment concepts for orthopaedic device-related infection. Clin Microbiol Infect 2012; 18: 1176-84.
42. Boakes AJ, Loo PS, Ridgway GL et al. Treatment of uncomplicated gonorrhoea in women with a combination of rifampicin and erythromycin. Br J Vener Dis 1984; 60: 309-11.
43. Oriel JD, Ridgway GL, Goldmeier D et al. Treatment of gonococcal urethritis in men with a rifampicin-erythromycin combination. Sex Transm Dis 1982; 9: 208-11.
44. Michalopoulos AS, Livaditis IG, Gougoutas V. The revival of fosfomycin. Int J Infect Dis 2011; 15: e732-9.
45. Popovic M, Steinort D, Pillai S et al. Fosfomycin: an old, new friend? Eur J Clin Microbiol Infect Dis 2010; 29: 127-42.
46. Southern PM Jr, Barnett JA, Luby JP et al. Acute gonococcal urethritis: failure of response to phosphonomycin therapy. Antimicrob Agents Chemother (Bethesda) 1969; 9: 343-5.
47. Lopez-Gracia J. Treatment of acute and subacute gonococcal urethritis with fosfomycin. Chemotherapy 1977; 23 Suppl 1: 293-300.